Production (Stage)
Stoke Therapeutics, Inc.
STOK
$9.18
-$0.18-1.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 601.20% | 362.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 601.20% | 362.08% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 601.20% | 362.08% | |||
| SG&A Expenses | 14.08% | 1.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.50% | 3.93% | |||
| Operating Income | 914.77% | 54.49% | |||
| Income Before Tax | 1,189.08% | 60.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1,176.88% | 60.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,176.88% | 60.34% | |||
| EBIT | 914.77% | 54.49% | |||
| EBITDA | 951.05% | 55.45% | |||
| EPS Basic | 1,161.37% | 60.82% | |||
| Normalized Basic EPS | 1,173.19% | 60.81% | |||
| EPS Diluted | 1,133.73% | 60.82% | |||
| Normalized Diluted EPS | 1,145.43% | 60.81% | |||
| Average Basic Shares Outstanding | 1.46% | 1.22% | |||
| Average Diluted Shares Outstanding | 4.15% | 1.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||